Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.

Leonetti A, Wever B, Mazzaschi G, Assaraf YG, Rolfo C, Quaini F, Tiseo M, Giovannetti E.

Drug Resist Updat. 2019 Sep 17;46:100644. doi: 10.1016/j.drup.2019.100644. [Epub ahead of print]

PMID:
31585395
2.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M.

Br J Cancer. 2019 Sep 30. doi: 10.1038/s41416-019-0573-8. [Epub ahead of print] Review.

PMID:
31564718
3.

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.

Esposito Abate R, Pasquale R, Sacco A, Piccirillo MC, Morabito A, Bidoli P, Finocchiaro G, Chiari R, Foltran L, Buosi R, Tiseo M, Giannetta L, Battiloro C, Fasola G, Romano G, Ciuffreda L, Frassoldati A, de Marinis F, Cappuzzo F, Normanno N.

Cancers (Basel). 2019 Sep 25;11(10). pii: E1431. doi: 10.3390/cancers11101431.

4.

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.

La Monica S, Minari R, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Galetti M, Digiacomo G, Riccardi F, Petronini PG, Tiseo M, Alfieri R.

Target Oncol. 2019 Oct;14(5):619-626. doi: 10.1007/s11523-019-00669-x.

PMID:
31502118
5.

Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study.

Ravanelli M, Agazzi GM, Milanese G, Roca E, Silva M, Tiseo M, Rondi P, Baggi A, Ganeshan B, Muri M, Panni S, Botti C, Sverzellati N, Maroldi R, Berruti A, Farina D.

Eur J Radiol. 2019 Sep;118:251-256. doi: 10.1016/j.ejrad.2019.07.019. Epub 2019 Jul 17.

PMID:
31439251
6.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
7.

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.

Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M.

Clin Transl Oncol. 2019 Aug 7. doi: 10.1007/s12094-019-02193-w. [Epub ahead of print]

PMID:
31392645
8.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.

PMID:
31319983
9.

Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.

Rebuzzi SE, Leonetti A, Tiseo M, Facchinetti F.

Immunotherapy. 2019 Aug;11(12):993-1003. doi: 10.2217/imt-2019-0107. Epub 2019 Jul 19. No abstract available.

10.

Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.

Van Den Borg R, Leonetti A, Tiseo M, Giovannetti E, Peters GJ.

Expert Rev Anticancer Ther. 2019 Jun;19(6):461-471. doi: 10.1080/14737140.2019.1624530. Epub 2019 May 31.

PMID:
31148500
11.

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.

La Monica S, Minari R, Cretella D, Flammini L, Fumarola C, Bonelli M, Cavazzoni A, Digiacomo G, Galetti M, Madeddu D, Falco A, Lagrasta CA, Squadrilli A, Barocelli E, Romanel A, Quaini F, Petronini PG, Tiseo M, Alfieri R.

J Exp Clin Cancer Res. 2019 May 28;38(1):222. doi: 10.1186/s13046-019-1240-x.

12.

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.

Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E.

Biochem Pharmacol. 2019 Aug;166:128-138. doi: 10.1016/j.bcp.2019.05.014. Epub 2019 May 10.

PMID:
31078602
13.

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.

Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M.

Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19.

PMID:
31027702
14.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D.

Oncologist. 2019 Apr 17. pii: theoncologist.2018-0737. doi: 10.1634/theoncologist.2018-0737. [Epub ahead of print]

PMID:
30996007
15.

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.

Fumarola C, Bozza N, Castelli R, Ferlenghi F, Marseglia G, Lodola A, Bonelli M, La Monica S, Cretella D, Alfieri R, Minari R, Galetti M, Tiseo M, Ardizzoni A, Mor M, Petronini PG.

Front Oncol. 2019 Mar 26;9:179. doi: 10.3389/fonc.2019.00179. eCollection 2019.

16.

Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.

Leonetti A, Facchinetti F, Minari R, Cortellini A, Rolfo CD, Giovannetti E, Tiseo M.

Cell Oncol (Dordr). 2019 Jun;42(3):261-273. doi: 10.1007/s13402-019-00441-3. Epub 2019 Apr 9. Review.

PMID:
30968324
17.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.

Clin Lung Cancer. 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.cllc.2019.02.006. Epub 2019 Feb 21.

PMID:
30885550
18.

Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine.

Russo U, Sabatino V, Nizzoli R, Tiseo M, Cappabianca S, Reginelli A, Carrafiello G, Brunese L, De Filippo M.

Future Oncol. 2019 Apr;15(10):1125-1134. doi: 10.2217/fon-2018-0527. Epub 2019 Mar 18.

PMID:
30880466
19.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C.

J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.

20.

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C.

Oncologist. 2019 Jun;24(6):e327-e337. doi: 10.1634/theoncologist.2018-0618. Epub 2019 Feb 22.

PMID:
30796151
21.

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.

Rihawi K, Giannarelli D, Galetta D, Delmonte A, Giavarra M, Turci D, Garassino M, Tiseo M, Barbieri F, Panni S, Ardizzoni A.

J Thorac Oncol. 2019 Mar;14(3):e57-e59. doi: 10.1016/j.jtho.2018.11.036. No abstract available.

PMID:
30782386
22.

Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?

Leonetti A, Facchinetti F, Tiseo M.

Ann Transl Med. 2018 Dec;6(Suppl 2):S110. doi: 10.21037/atm.2018.11.69. No abstract available.

23.

Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?

Facchinetti F, Majori M, Sabato M, Gnetti L, Tiseo M.

Immunotherapy. 2019 Feb;11(3):161-166. doi: 10.2217/imt-2018-0136.

PMID:
30730279
24.

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review.

Abbate MI, Cortinovis DL, Tiseo M, Vavalà T, Cerea G, Toschi L, Canova S, Colonese F, Bidoli P.

Future Oncol. 2019 Mar;15(9):989-994. doi: 10.2217/fon-2018-0469. Epub 2019 Jan 25. Review.

PMID:
30681378
25.

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.

Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenkov Y, Ohe Y.

Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.

PMID:
30659024
26.

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.

Mazzaschi G, Facchinetti F, Missale G, Canetti D, Madeddu D, Zecca A, Veneziani M, Gelsomino F, Goldoni M, Buti S, Bordi P, Aversa F, Ardizzoni A, Quaini F, Tiseo M.

Lung Cancer. 2019 Jan;127:153-163. doi: 10.1016/j.lungcan.2018.11.038. Epub 2018 Nov 29.

PMID:
30642544
27.

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.

Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F.

Clin Lung Cancer. 2019 Mar;20(2):e186-e194. doi: 10.1016/j.cllc.2018.11.005. Epub 2018 Nov 20.

PMID:
30563752
28.

MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.

Leonetti A, Assaraf YG, Veltsista PD, El Hassouni B, Tiseo M, Giovannetti E.

Drug Resist Updat. 2019 Jan;42:1-11. doi: 10.1016/j.drup.2018.11.002. Epub 2018 Nov 28. Review.

PMID:
30544036
29.

Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial.

Facchinetti F, Tiseo M.

Chin Clin Oncol. 2018 Oct 10. pii: cco.2018.09.04. doi: 10.21037/cco.2018.09.04. [Epub ahead of print] No abstract available.

30.

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.

Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Gilli A, Honeywell R, Chartoire M, Peters GJ, Giovannetti E; Italian Oncological Group of Clinical Research (GOIRC).

Br J Cancer. 2018 Nov;119(11):1326-1331. doi: 10.1038/s41416-018-0307-3. Epub 2018 Nov 8.

PMID:
30405211
31.

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.

Del Re M, Bordi P, Rofi E, Restante G, Valleggi S, Minari R, Crucitta S, Arrigoni E, Chella A, Morganti R, Tiseo M, Petrini I, Danesi R.

Br J Cancer. 2018 Nov;119(10):1252-1258. doi: 10.1038/s41416-018-0238-z. Epub 2018 Nov 6.

PMID:
30397287
32.

Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in EGFR-mutated non-small cell lung cancer.

Facchinetti F, Bozzetti F, Minari R, Ceccon G, Zielli T, Florindo I, Crisi G, Tiseo M.

Tumori. 2018 Dec;104(6):NP29-NP33. doi: 10.1177/0300891618809826. Epub 2018 Nov 5.

PMID:
30392443
33.

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S.

Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080.

PMID:
30326787
34.

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S.

N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.

35.

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.

Facchinetti F, Bordi P, Leonetti A, Buti S, Tiseo M.

Drug Des Devel Ther. 2018 Sep 10;12:2857-2873. doi: 10.2147/DDDT.S124380. eCollection 2018. Review.

36.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE.

Clin Cancer Res. 2019 Jan 1;25(1):64-72. doi: 10.1158/1078-0432.CCR-18-1590. Epub 2018 Sep 11.

PMID:
30206164
37.

Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib.

Facchinetti F, Gnetti L, Balestra V, Silva M, Silini EM, Ventura L, Majori M, Bordi P, Tiseo M.

Invest New Drugs. 2019 Apr;37(2):360-363. doi: 10.1007/s10637-018-0652-3. Epub 2018 Aug 1.

PMID:
30066208
38.

Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non-Small-cell Lung Cancer: Clinical and Budget Effect.

Paolini D, Tiseo M, Demma F, Furneri G, Dionisi M, Akkermans M, Marchetti A.

Clin Lung Cancer. 2018 Sep;19(5):e735-e743. doi: 10.1016/j.cllc.2018.05.012. Epub 2018 May 31.

39.

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.

Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri L, Rapacchi E, Mazzaschi G, Leonardi F, Quaini F, Ardizzoni A, Missale G, Tiseo M.

Immunotherapy. 2018 Jun;10(8):681-694. doi: 10.2217/imt-2017-0175.

PMID:
29882691
40.

Is the door open to further investigation with antiangiogenesis in SCLC?

Tiseo M, Boni L, Ardizzoni A.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1127-S1128. doi: 10.21037/jtd.2018.03.87. No abstract available.

41.

Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.

Facchinetti F, Gnetti L, Caruana P, Fornaroli F, Luigi de'Angelis G, Sabato M, Ferri L, Cosenza A, Bordi P, Tiseo M.

Clin Lung Cancer. 2018 Sep;19(5):e591-e596. doi: 10.1016/j.cllc.2018.04.013. Epub 2018 May 5. No abstract available.

PMID:
29801705
42.

No room for statins in the quest for survival benefits in small cell lung cancer.

Facchinetti F, Tiseo M.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S131-S133. doi: 10.21037/tlcr.2018.03.07. No abstract available.

43.

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN.

J Clin Oncol. 2018 Sep 10;36(26):2693-2701. doi: 10.1200/JCO.2017.77.5841. Epub 2018 May 16.

PMID:
29768119
44.

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.

Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.

Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.

PMID:
29753703
45.

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.

Callegari D, Ranaghan KE, Woods CJ, Minari R, Tiseo M, Mor M, Mulholland AJ, Lodola A.

Chem Sci. 2018 Feb 12;9(10):2740-2749. doi: 10.1039/c7sc04761d. eCollection 2018 Mar 14.

46.

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, Tiseo M, Planchard D.

Cancer Treat Rev. 2018 May;66:82-94. doi: 10.1016/j.ctrv.2018.04.006. Epub 2018 Apr 24. Review.

PMID:
29729495
47.

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

Minari R, Bordi P, La Monica S, Squadrilli A, Leonetti A, Bottarelli L, Azzoni C, Lagrasta CAM, Gnetti L, Campanini N, Petronini PG, Alfieri R, Tiseo M.

J Thorac Oncol. 2018 Jun;13(6):e89-e91. doi: 10.1016/j.jtho.2018.03.013. Epub 2018 Mar 27. No abstract available.

48.

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.

Cortellini A, Bersanelli M, Buti S, Gambale E, Atzori F, Zoratto F, Parisi A, Brocco D, Pireddu A, Cannita K, Iacono D, Migliorino MR, Gamucci T, De Tursi M, Sidoni T, Tiseo M, Michiara M, Papa A, Angius G, Tomao S, Fargnoli MC, Natoli C, Ficorella C.

Immunotherapy. 2018 Jun;10(8):643-655. doi: 10.2217/imt-2017-0167. Epub 2018 Mar 22.

49.

ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma".

Mengoli MC, Bertolini F, Maur M, Barbieri F, Longo L, Gasparri P, Tiseo M, Rossi G.

Pathologica. 2017 Dec;109(4):408-411.

PMID:
29449735
50.

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH: A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study.

Mengoli MC, Rossi G, Cavazza A, Franco R, Marino FZ, Migaldi M, Gnetti L, Silini EM, Ampollini L, Tiseo M, Lococo F, Fournel L, Spagnolo P, Cottin V, Colby TV.

Am J Surg Pathol. 2018 May;42(5):646-655. doi: 10.1097/PAS.0000000000001033.

PMID:
29438170

Supplemental Content

Support Center